

**First Regular Session
Sixty-seventh General Assembly
STATE OF COLORADO**

PREAMENDED

*This Unofficial Version Includes Committee
Amendments Not Yet Adopted on Second Reading*

LLS NO. 09-0394.01 Kristen Forrestal

HOUSE BILL 09-1059

HOUSE SPONSORSHIP

Primavera,

SENATE SPONSORSHIP

(None),

House Committees

Health and Human Services

Senate Committees

A BILL FOR AN ACT

101 **CONCERNING THE CONTINUATION OF HEALTH CARE COVERAGE WHILE**
102 **PARTICIPATING IN A CLINICAL TRIAL.**

Bill Summary

(Note: This summary applies to this bill as introduced and does not necessarily reflect any amendments that may be subsequently adopted.)

Requires all individual and group health benefit plans to provide coverage for routine patient care costs while the covered person participates in a clinical trial or study as long as the coverage is a benefit that the covered person would receive if he or she were receiving standard chronic disease treatment outside of the clinical trial or study. Requires the clinical trial or study to meet specific standards of approval.

Shading denotes HOUSE amendment. Double underlining denotes SENATE amendment.
Capital letters indicate new material to be added to existing statute.
Dashes through the words indicate deletions from existing statute.

1 *Be it enacted by the General Assembly of the State of Colorado:*

2 **SECTION 1.** 10-16-104, Colorado Revised Statutes, is amended
3 BY THE ADDITION OF A NEW SUBSECTION to read:

4 **10-16-104. Mandatory coverage provisions - definitions.** (20)

5 **Clinical trials and studies.** (a) ALL INDIVIDUAL AND GROUP HEALTH
6 BENEFIT PLANS SHALL PROVIDE COVERAGE FOR ROUTINE PATIENT CARE
7 COSTS THAT A POLICY OR CERTIFICATE HOLDER, OR HIS OR HER
8 DEPENDENT, RECEIVES DURING A CLINICAL TRIAL IF:

9 (I) THE COVERED PERSON'S TREATING PHYSICIAN, WHO IS
10 PROVIDING COVERED HEALTH CARE SERVICES TO THE PERSON UNDER THE
11 HEALTH BENEFIT PLAN CONTRACT, RECOMMENDS PARTICIPATION IN THE
12 CLINICAL TRIAL AFTER DETERMINING THAT PARTICIPATION IN THE
13 CLINICAL TRIAL HAS A MEANINGFUL POTENTIAL TO BENEFIT THE COVERED
14 PERSON;

15 (II) THE CLINICAL TRIAL OR STUDY IS APPROVED UNDER THE
16 SEPTEMBER 19, 2000, MEDICARE NATIONAL COVERAGE DECISION
17 REGARDING CLINICAL TRIALS, AS AMENDED;

18 (III) THE PATIENT CARE IS PROVIDED BY A CERTIFIED, REGISTERED,
19 OR LICENSED HEALTH CARE PROVIDER PRACTICING WITHIN THE SCOPE OF
20 HIS OR HER PRACTICE AND THE FACILITY AND PERSONNEL PROVIDING THE
21 TREATMENT HAVE THE EXPERIENCE AND TRAINING TO PROVIDE THE
22 TREATMENT IN A COMPETENT MANNER;

23 (IV) PRIOR TO PARTICIPATION IN A CLINICAL TRIAL OR STUDY, THE
24 COVERED PERSON HAS SIGNED A STATEMENT OF CONSENT INDICATING
25 THAT THE COVERED PERSON HAS BEEN INFORMED OF THE PROCEDURE TO
26 BE UNDERTAKEN, ALTERNATIVE METHODS OF TREATMENT, THE GENERAL

1 NATURE AND EXTENT OF THE RISKS ASSOCIATED WITH PARTICIPATION IN
2 THE CLINICAL TRIAL OR STUDY, THE COVERAGE PROVIDED BY AN
3 INDIVIDUAL OR GROUP HEALTH BENEFIT PLAN WILL BE CONSISTENT WITH
4 THE COVERAGE PROVIDED IN THE COVERED PERSON'S HEALTH BENEFIT
5 PLAN, AND ALL OUT-OF-NETWORK RATES WILL APPLY; AND

6 (V) THE COVERED PERSON SUFFERS FROM A CONDITION THAT IS
7 DISABLING, PROGRESSIVE, OR LIFE-THREATENING.

8 (b) THE COVERAGE REQUIRED PURSUANT TO PARAGRAPH (a) OF
9 THIS SUBSECTION (20) DOES NOT INCLUDE:

10 (I) ANY PORTION OF THE CLINICAL TRIAL OR STUDY THAT IS PAID
11 FOR BY A GOVERNMENT OR A BIOTECHNICAL, PHARMACEUTICAL, OR
12 MEDICAL INDUSTRY;

13 (II) COVERAGE FOR ANY DRUG OR DEVICE THAT IS PAID FOR BY
14 THE MANUFACTURER, DISTRIBUTOR, OR PROVIDER OF THE DRUG OR
15 DEVICE;

16 (III) EXTRANEOUS EXPENSES RELATED TO PARTICIPATION IN THE
17 CLINICAL TRIAL OR STUDY INCLUDING, BUT NOT LIMITED TO, TRAVEL,
18 HOUSING, AND OTHER EXPENSES THAT A PARTICIPANT OR PERSON
19 ACCOMPANYING A PARTICIPANT MAY INCUR;

20 (IV) AN ITEM OR SERVICE THAT IS PROVIDED SOLELY TO SATISFY
21 A NEED FOR DATA COLLECTION OR ANALYSIS THAT IS NOT DIRECTLY
22 RELATED TO THE CLINICAL MANAGEMENT OF THE PARTICIPANT; ■

23 (V) COSTS FOR THE MANAGEMENT OF RESEARCH RELATING TO THE
24 CLINICAL TRIAL OR STUDY; OR

25 (VI) HEALTH CARE SERVICES THAT, EXCEPT FOR THE FACT THAT
26 THEY ARE BEING PROVIDED IN A CLINICAL TRIAL, ARE OTHERWISE
27 SPECIFICALLY EXCLUDED FROM COVERAGE UNDER THE COVERED PERSON'S

1 HEALTH PLAN.

2 (c) NOTHING IN THIS SUBSECTION (20) SHALL:

3 (I) PRECLUDE A CARRIER FROM ASSERTING THE RIGHT TO SEEK
4 REIMBURSEMENT FROM THE CLINICAL TRIAL OR STUDY FOR EXPENSES
5 ARISING FROM COMPLICATIONS CAUSED BY A DRUG OR DEVICE USED IN THE
6 CLINICAL TRIAL OR STUDY;

7 (II) BE INTERPRETED TO PROVIDE A PRIVATE CAUSE OF ACTION
8 AGAINST A CARRIER FOR DAMAGES ARISING AS A RESULT OF COMPLIANCE
9 WITH THIS SECTION.

10 (d) FOR THE PURPOSES OF THIS SECTION:

11 (I) "CLINICAL TRIAL" MEANS AN EXPERIMENT IN WHICH A DRUG OR
12 DEVICE IS ADMINISTERED TO, DISPENSED TO, OR USED BY ONE OR MORE
13 HUMAN SUBJECTS. AN EXPERIMENT MAY INCLUDE THE USE OF A
14 COMBINATION OF DRUGS AS WELL AS THE USE OF A DRUG IN COMBINATION
15 WITH AN ALTERNATIVE THERAPY OR DIETARY SUPPLEMENT.

16 (II) "ROUTINE PATIENT CARE COST" MEANS ALL ITEMS AND
17 SERVICES THAT ARE A BENEFIT UNDER A HEALTH COVERAGE PLAN THAT
18 WOULD BE COVERED IF THE COVERED PERSON WERE NOT INVOLVED IN
19 EITHER THE EXPERIMENTAL OR THE CONTROL ARMS OF A CLINICAL TRIAL;
20 EXCEPT THE INVESTIGATIONAL ITEM OR SERVICE, ITSELF; ITEMS AND
21 SERVICES PROVIDED SOLELY TO SATISFY DATA COLLECTION AND ANALYSIS
22 NEEDS AND THAT ARE NOT USED IN THE DIRECT CLINICAL MANAGEMENT
23 OF THE PATIENT; ITEMS AND SERVICES CUSTOMARILY PROVIDED BY THE
24 RESEARCH SPONSORS FREE OF CHARGE FOR ANY ENROLLEE IN THE TRIAL;
25 ROUTINE COSTS IN CLINICAL TRIALS INCLUDE ITEMS OR SERVICES THAT ARE
26 TYPICALLY PROVIDED ABSENT A CLINICAL TRIAL; ITEMS OR SERVICES
27 REQUIRED SOLELY FOR THE PROVISION OF THE INVESTIGATIONAL ITEMS OR

1 SERVICES, THE CLINICALLY APPROPRIATE MONITORING OF THE EFFECTS OF
2 THE ITEM OF SERVICE, OR THE PREVENTION OF COMPLICATIONS; AND ITEMS
3 OR SERVICES NEEDED FOR REASONABLE AND NECESSARY CARE ARISING
4 FROM THE PROVISION OF AN INVESTIGATIONAL ITEM OR SERVICE,
5 INCLUDING THE DIAGNOSIS OR TREATMENT OF COMPLICATIONS.

6 **SECTION 2. Act subject to petition - effective date -**
7 **applicability.** (1) This act shall take effect at 12:01 a.m. on the day
8 following the expiration of the ninety-day period after final adjournment
9 of the general assembly that is allowed for submitting a referendum
10 petition pursuant to article V, section 1 (3) of the state constitution,
11 (August 4, 2009, if adjournment sine die is on May 6, 2009); except that,
12 if a referendum petition is filed against this act or an item, section, or part
13 of this act within such period, then the act, item, section, or part, if
14 approved by the people, shall take effect on the date of the official
15 declaration of the vote thereon by proclamation of the governor.

16 (2) The provisions of this act shall apply to policies, contracts, and
17 certificates of insurance issued or renewed on or after the applicable
18 effective date of this act.